不同剂量瑞舒伐他汀钙对不稳定型心绞痛患者症状发作频率、不良反应及临床效果观察

Effect of Different Doses of Rosuvastatin Calcium on the Frequency of Symptom Attack,Adverse Reactions and Clinical Effects in Patients with Unstable Angina Pectoris

目的 观察不同剂量瑞舒伐他汀钙对不稳定型心绞痛患者症状发作频率、不良反应及临床效果。方法 选取我院自2017年11月至2019年1月收治的不稳定型心绞痛患者154例,应用数字表随机法分成两组,高剂量组(n=77)给予患者20 mg瑞舒伐他汀钙胶囊,每晚1次,低剂量组(n=77)给予患者10 mg瑞舒伐他汀钙胶囊,每晚1次,对两组患者经过不同治疗之后的治疗有效率、治疗前后的LVEDD、LVEF指标、心电图ST段、心绞痛发作次数和发作时间、用药不良反应发生率、疼痛、负面情绪、睡眠质量、生活质量等进行统计和比较。结果 (1)高剂量组(74例,占96.10%)治疗后的总有效率明显比低剂量组(67例,占87.01%)更高,差异有统计学意义(P <0.05)。(2)治疗前,两组患者的LVEDD、LVEF指标、心电图ST段、心绞痛发作次数和心绞痛发作时间的差异无显著性(P> 0.05);治疗后,两组患者的上述指标均有改善,但高剂量组的改善效果相对低剂量组而言更突出,差异有统计学意义(P <0.05)。(3)治疗前,两组患者的VAS评分、HAMA评分、HAMD评分、PSQI评分的差异无显著性(P> 0.05),治疗后,两组患者的上述指标均有改善,但高剂量组的改善效果相对低剂量组而言更突出,差异有统计学意义(P <0.05)。(4)高剂量组(7例,占9.09%)患者治疗后的不良反应发生率相比低剂量组(5例,占6.49%)而言更高,但差异无显著性(P> 0.05)。(5)治疗前,两组患者的SF-36生活质量量表评分的差异无显著性(P> 0.05);治疗后,两组患者的SF-36生活质量量表评分均有改善,但高剂量组的改善效果相对低剂量组而言更突出,差异有统计学意义(P <0.05)。结论 高剂量和低剂量的瑞舒伐他汀都可适用于对不稳定性心绞痛患者的治疗,但相对于低剂量而言,高剂量用药能更好地提升治疗有效率,且安全性较高,可以改善患者的临床症状,减轻患者的疼痛、负面心理和睡眠质量并提高整体生活质量,值得推荐。

Objective To observe the frequency of symptom attacks,adverse reactions and clinical effects of different doses of rosuvastatin calcium in patients with unstable angina pectoris.Methods A total of 154 patients with unstable angina pectoris who were treated in our hospital from November 2017 to January 2019 were selected and randomly divided into two groups by digital table method.The high-dose group(n=77) was given 20 mg of rosuvastatin.Calcium capsules,once a night,and the low-dose group(n=77) were given 10 mg rosuvastatin calcium capsules,once a night.LVEF index,ECG ST segment,angina attack times and attack time,incidence of adverse drug reactions,pain,negative emotions,sleep quality,quality of life,etc.were statistically and compared.Results(1) The total effective rate of the high-dose group(74 cases,accounting for 96.10%) after treatment was significantly higher than that of the low-dose group(67 cases,accounting for 87.01%),and the difference was consistent with the statistical standard(P<0.05).(2) Before treatment,there was no significant difference in LVEDD,LVEF index,ECG ST segment,angina attack times and angina attack time between the two groups(P>0.05).After treatment,the above indexes of the two groups were improved.However,the improvement effect of the high-dose group was more prominent than that of the low-dose group,and the difference was consistent with the statistical standard(P<0.05).The difference was not significant(P>0.05).After treatment,the above indexes of the two groups were improved,but the improvement effect of the high-dose group was more prominent than that of the low-dose group,and the difference was consistent with the statistical standard(P<0.05).(4) The incidence of adverse reactions in the high-dose group(7 cases,accounting for 9.09%) after treatment was higher than that in the low-dose group(5 cases,accounting for 6.49%),but the difference was not significant(P>0.05).(5) Before treatment,there was no significant difference in SF-36 quality of life scale scores between the two groups(P>0.05).However,the improvement effect of the high-dose group was more prominent than that of the low-dose group,and the difference was consistent with the statistical standard(P<0.05).Conclusion Both high-dose and low-dose rosuvastatin are suitable for the treatment of patients with unstable angina pectoris,but compared with low-dose,high-dose medication can better improve the treatment efficiency and has higher safety,can improve the clinical symptoms of patients,reduce the pain,negative psychology and sleep quality of patients,and improve the overall quality of life,which is worth recommending.